17yo blood sample with SARS antibodies could be new secret weapon against CORONAVIRUS – study
Scientists based in Switzerland and the United States examined 25 different types of antibodies, which each target different protein spikes on the virus, which it uses to infiltrate host cells and infect them with genetic material. From this list of antibodies, the researchers identified eight that could bind to both Covid-19 and the infected cells.
One in particular – S309 – was shown to have “particularly strong neutralizing activity” when faced with Covid-19. When they combined S309 with other, less potent antibodies, the team found that they could limit its ability to mutate – though, for now at least, in a laboratory setting only.Also on rt.com ‘THIS WILL KILL YOU’: Media goes into anti-HCQ panic mode after Trump says he’s taking the drug to fend off Covid-19
Severe Acute Respiratory Syndrome, or SARS, and the pathogen which causes Covid-19 are both coronaviruses, with similar origins (both believed to have originated in animals) and similar structures, though dramatically different consequences for humanity.
Now, however, using antibodies from a survivor of the SARS outbreak which killed 774, the researchers believe they have a “proof-of-concept” for treating the coronavirus pandemic which has killed over 318,000 worldwide.
“These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease,” the researchers wrote.
The antibodies are now on a fast-track development and testing path at Vir Biotechnology to expedite their development for human testing. Vir Biotechnology, the company behind the study, specializes in combining immunology research and cutting-edge technologies with a focus on treating and curing infectious diseases.Also on rt.com Game changer: German scientists find antibodies that BLOCK coronavirus from spreading further
“We still need to show that this antibody is protective in living systems, which has not yet been done,” says senior author David Veesler, assistant professor of biochemistry at the University of Washington School of Medicine.
Like this story? Share it with a friend!